Skip to main content

Table 5 Delivery location characteristics by group and period

From: A multi-faceted intervention including antenatal corticosteroids to reduce neonatal mortality associated with preterm birth: a case study from the Guatemalan Western Highlands

Characteristic

Pre trial period

Trial period

Crude Estimate of Change in Prevalencea

Crude Estimate of Difference in Change in Prevalenceb

Adjusted Estimate of Difference in Change in Prevalence (95 % CI), p-valuec

Intervention

Control

Intervention

Control

Intervention

Control

Deliveries, N

2,041

2,305

3,766

3,960

    

Delivery location, (%)

       

--

 Hospital

24.9

29.8

46.8

44.3

21.9

14.5

7.4

 

 Clinic

2.5

2.3

7.0

1.1

4.5

−1.2

5.7

 

 Home/Other

72.6

67.9

46.2

54.6

−26.4

−13.3

−13.1

 

Birth at facility level (hospital or clinic), (%)

27.4

32.1

53.8

45.4

26.4

13.3

13.1

7.70 (−2.61, 18.01), p = 0.1434

Birth at facility with C-section or any neonatal care capabilitiesd, (%)

26.2

31.0

53.3

45.2

27.1

14.2

12.9

7.36 (−3.39, 18.12), p = 0.1797

 Birth at facility that has C-section capabilities, (%)

26.1

31.0

47.5

40.5

21.4

9.5

11.9

--

 Birth at facility that has bag and mask capabilities, (%)

10.7

11.1

43.7

41.9

33.0

30.8

2.2

--

 Birth at facility that has oxygen or mechanical ventilation capabilities, (%)

20.8

26.6

47.4

42.6

26.6

16.0

10.6

--

  1. aCrude change in prevalence = (percentage during the trial period minus percentage during the pretrial period)
  2. bCrude difference in change in prevalence = (percentage during the trial period minus percentage during the pretrial period for the treatment group) minus (percentage during the trial period minus percentage during the pretrial period for control group)
  3. cTest to assess whether the change between the pretrial and trial periods differed by treatment group. The adjusted percent difference of the percent differences is the estimate of the difference in changes in probability from pretrial to trial period for the given characteristic in the treatment arm minus changes in probability from the pretrial to trial period for the given characteristic in the control arm. P-values were calculated from generalized linear models accounting for the cluster-level variance and adjusted for randomization strata
  4. dNeonatal care capabilities include bag and mask, oxygen or mechanical ventilation. Facilities with any of the capabilities are tested for differences between the pretrial and trial periods by treatment group